AXA/2026/1Q/Activity indicators press release

Document info
Organization	AXA
Year	2026
Period	1Q
Period label	1Q26
Document type	Press release
Publication date	2026-05-05
Market timing	Pre-market
Language	English
Pages	16
Source	Original URL
Archive file	.md file

This article summarizes AXA's 1Q 2026 activity indicators press release, published on 5 May 2026.

1Q26 highlights

• Gross written premiums & other revenues +6% vs. 1Q25 to EUR 38.0bn ^{p. 1}
  • Property & Casualty premiums +4% to EUR 21.5bn ^{p. 1}
    • Retail premiums +7%, with +4% from price effect and +3% from volumes ^{p. 1}
    • Commercial premiums +3%, with equal contributions from price effect and volumes ^{p. 1}
  • Life & Health premiums +8% to EUR 16.5bn ^{p. 1}
    • Life premiums +8% ^{p. 1}
    • Health premiums +8% ^{p. 1}
• Life & Health NB CSM +4% ^{p. 1}
• Net flows EUR +2.7bn ^{p. 1}
• Solvency II ratio 211% as of March 31, 2026 ^{p. 1}
  • Down -4 points vs. January 1, 2026 (post-grandfathering period) ^{p. 1}
  • Reflects resilience in a volatile environment ^{p. 1}

Outlook

• AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the 6-8% plan target range ^{p. 1}
• AXA will present its new strategic plan for 2027-2029 on September 15, 2026 ^{p. 1}

"AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," said Alban de Mailly Nesle, Chief Financial Officer of AXA . "This performance underscores the continued robust expansion of our P&C businesses in both Retail and Commercial, with growth well balanced between pricing and volumes, while Life & Health revenues reflect the continuation of last year's strong momentum." ^{p. 1}

" In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan. ^{p. 1}

"I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA ." ^{p. 1}

Press release

• The press release was issued in Paris on May 5, 2026, at 5:45pm CET ^{p. 1}
• The document covers 1Q26 Activity indicators and sustained revenue momentum ^{p. 1}
• All footnotes for this press release are on page 7 ^{p. 1}
• Key highlights are presented ^{p. 2}

1Q26 key highlights

Key figures for gross written premiums and other revenues in 1Q25 and 1Q26. ^{p. 2}

Key figures (EUR billion, unless otherwise noted)	1Q25	1Q26	Change	Change LFL
Gross written premiums and other revenues (footnote: Change in gross written premiums & other revenues, new business value (“NBV”), present value of expected premiums (“PVEP”) and new business value margin (“NBV Margin”) is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms are defined in the glossary section of this press release.)	37.0	38.0	+3%	+6%
o/w Property & Casualty	21.0	21.5	+2%	+4%
o/w Life & Health	15.5	16.5	+7%	+8%
o/w Asset Management	0.4	n.m.	n.m.	n.m.

Solvency II ratio key figures for FY25, January 1, 2026, and 1Q26. ^{p. 2}

Key figures (EUR billion, unless otherwise noted)	FY25	January 1, 2026	1Q26	Change vs. January 1, 2026
Solvency II ratio (%) (footnote: The Solvency II ratio is estimated primarily using AXA’s internal model calibrated based on an adverse 1/200 years shock. It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on the full-year dividend of Euro 2.32 per share to be paid in 2026 for FY25 and annual share buyback of Euro 1.25 billion announced on February 26, 2026. Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock- based compensation. Dividends and share buybacks are proposed by the Board, at its discretion based on a variety of factors described in AXA’s 2025 Universal Registration Document and then submitted to AXA’s shareholders for approval. This estimate should not be considered in any way to be an indication of the actual dividend and share buyback amounts, if any, for the 2026 financial year. For further information on AXA’s internal model and Solvency II disclosures, please refer to AXA Group’s Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA’s website (www.axa.com).)	224%	215%	211%	-4pts

Activity indicators

• Total gross written premiums & other revenues +6% ^{p. 2}
  • Driven by Property & Casualty (+4%) ^{p. 2}
    • Personal lines +7%, driven by higher volumes and favorable price effect ^{p. 2}
    • Commercial lines +3%, from higher volumes (notably at AXA XL Insurance) and favorable price effect (mainly in SME & Mid-market business in Europe and France) ^{p. 2}
    • Partially offset by AXA XL Reinsurance -7%, reflecting discipline in softening market conditions ^{p. 2}
  • Driven by Life & Health (+8%) ^{p. 2}
    • Life premiums +8%, driven by strong sales in Unit-Linked (+16%) and G/A (+9%) across all geographies, and Protection (+4%) from strong sales in Protection with Savings in Hong Kong and Japan ^{p. 2}
    • Health premiums +8%, driven by favorable price effects across all geographies ^{p. 2}
• Solvency II ratio was 211% as of March 31, 2026 ^{p. 2}
  • On January 1, 2026, the Solvency II ratio was 215% following the end of the grandfathering period ^{p. 2}
  • The grandfathering period ending resulted in a -10 points decrease vs. December 31, 2025 ^{p. 2}
  • The Solvency II ratio was down -4 points vs. January 1, 2026 ^{p. 2}
    • Reflects a strong operating return (+7 points), less accrued dividend and annual share buyback for 1Q26 (-6 points) ^{p. 2}
    • More than offset by unfavorable financial market movements (-4 points), notably from higher inflation expectations and elevated equity and interest rate volatility ^{p. 2}
  • (footnote: Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, at which point they ceased to qualify as capital under Solvency II, as disclosed in AXA’s respective press releases on its 9M25 Activity Indicators and Full Year 2025 Earnings, each published on www.axa.com.) ^{p. 2}

Property & Casualty

Property & Casualty gross written premiums and other revenues in 1Q25 and 1Q26. ^{p. 3}

Key figures (EUR billion, unless otherwise noted)	1Q25	1Q26	Change LFL	1Q26 Price effect (in %) (footnote: Price effect is calculated as a percentage of total gross written premiums of the prior year.)
Gross written premiums and other revenues (footnote: Change in gross written premiums & other revenues, new business value (“NBV”), present value of expected premiums (“PVEP”) and new business value margin (“NBV Margin”) is on a comparable basis (constant forex, scope and methodology), unless otherwise indicated. These and other terms are defined in the glossary section of this press release.)	21.0	21.5	+4%	+1.9%
o/w Commercial lines 5 (footnote: Natural catastrophe charges include natural catastrophe losses regardless of event size.)	13.2	13.2	+3%	+1.5%
o/w Personal lines	6.4	7.0	+7%	+4.0%
o/w AXA XL Reinsurance	1.4	1.2	-7%	-3.9%

• Gross written premiums & other revenues +4% to EUR 21.5bn ^{p. 3}
• Personal lines +7% to EUR 7.0bn, driven by: ^{p. 3}
  • Europe: +7%, from favorable price effects across geographies (except UK & Ireland) and higher volumes ^{p. 3}
  • France: +8%, with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect ^{p. 3}
  • Asia, Africa & EME LATAM: +7%, mainly driven by higher average premiums in Türkiye and higher volumes in Mexico ^{p. 3}
• Commercial lines +3% to EUR 13.2bn, mainly from: ^{p. 3}
  • AXA XL Insurance: +2%, from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty ^{p. 3}
    • Pricing overall remains stable versus 1Q25 ^{p. 3}
  • France: +6%, from both favorable price effect and higher volumes ^{p. 3}
  • Asia, Africa & EME-LATAM: +10%, mainly driven by higher average premiums in Türkiye ^{p. 3}
• AXA XL Reinsurance -7% to EUR 1.2bn, reflecting lower volumes ^{p. 3}
  • Consistent with focus on maintaining profitability in a softer market environment ^{p. 3}
  • Pricing down -4% ^{p. 3}
• Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget ^{p. 3}
• The annual natural catastrophe budget of ca. 4.5 points of combined ratio is maintained ^{p. 3}

Life & Health

Life & Health key figures for gross written premiums, NB CSM, NBV, and net flows. ^{p. 4}

Key figures (EUR billion, unless otherwise noted)	1Q25	1Q25 Updated*	1Q26	Change vs. 1Q25 updated LFL
Gross written premiums and other revenues	15.5	—	16.5	+8%
o/w Life	9.8	—	10.5	+8%
o/w Health	5.6	—	5.9	+8%
PVNBP	13.7	13.0	13.8	+8%
NB CSM (pre-tax)	0.6	0.6	0.6	+4%
NBV (post-tax)	0.7	0.6	0.6	+1%
NBV margin (footnote: Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.)	4.9%	4.8%	4.4%	-0.3pt
Net flows	+2.5	—	+2.7	—

• For comparability, 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions ^{p. 4}
• All year-on-year changes are on a comparable basis versus the updated 1Q25 figures ^{p. 4}
• Gross written premiums & other revenues +8% to EUR 16.5bn ^{p. 4}
• Life premiums +8% to EUR 10.5bn, driven by: ^{p. 4}
  • Unit-Linked: +16%, from continued positive sales momentum across geographies ^{p. 4}
  • G/A Savings: +9%, mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland ^{p. 4}
  • Protection: +4%, primarily from continued success of Protection with G/A savings in Hong-Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland ^{p. 4}
• Health premiums +8% to EUR 5.9bn, driven by favorable price effects across all geographies ^{p. 4}
• PVEP +8% to EUR 13.8bn, driven by: ^{p. 4}
  • Life: +10%, reflecting strong sales across geographies in both Savings (+14%) and Protection (+6%), partly offset by lower Group Life sales in Switzerland ^{p. 4}
  • Health: +4%, mainly due to higher Group business volumes in France, partly offset by Japan ^{p. 4}
• NB CSM (pre-tax) +4% to EUR 0.6bn ^{p. 4}
  • Driven by strong Savings and Protection sales across most geographies ^{p. 4}
  • Partially offset by unfavorable mix, including lower Group Life sales in Switzerland and Health sales in Japan ^{p. 4}
• NBV (post-tax) +1% to EUR 0.6bn ^{p. 4}
  • NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China ^{p. 4}
• NBV margin -0.3 points to 4.4% ^{p. 4}
• Net flows EUR +2.7bn, compared to EUR +2.5bn in 1Q25, driven by: ^{p. 4}
  • Protection: EUR +1.8bn, mainly in Hong Kong and Switzerland (Individual Life), and Japan (Protection with Unit-Linked product) ^{p. 4}
  • Unit-Linked: EUR +0.7bn, primarily in France ^{p. 4}
  • G/A Savings: EUR -0.8bn, reflecting inflows in capital-light G/A savings (EUR +0.7bn) more than offset by outflows in traditional G/A Savings (EUR -1.5bn) ^{p. 4}
  • Health: EUR +1.0bn, mostly from Germany, France, and Japan ^{p. 4}

Ratings

Insurer financial strength and AXA's credit ratings from S&P, Moody's, and AM Best. ^{p. 5}

—	—	Insurer financial strength ratings			AXA's credit ratings (footnote: Restricted Tier 1: “A-” by Standard & Poor’s and “A3(hyb)” by Moody’s. Tier 2: “A” by Standard & Poor’s and “A1(hyb)” by Moody’s.)
S&P Global Ratings	March 11, 2026	AA-	AA	Stable	AA-	A-1+
Moody's Investor Service	October 8, 2025	Aa2	Aa2	Stable	Aa3	P-1
AM Best	October 9, 2025	A+ Superior	—	Stable	aa Superior	—

Glossary

• Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% ^{p. 5}
• Contractual service margin ('CSM'): a component of the carrying amount of the asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders ^{p. 5}
• Gross written premiums and other revenues: insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business) ^{p. 5}
  • Other Revenues represent premiums and fees collected on activities other than insurance (i.e., banking, services, and asset management activities) ^{p. 5}
• New business contractual service margin ('NB CSM'): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided ^{p. 5}
• New business value ('NBV'): the value of newly issued contracts during the current year ^{p. 5}
  • Consists of the sum of (i) the NB CSM, (ii) the present value of the future profits of Short-Term Business newly issued contracts during the period (carried by Life entities, considering expected renewals), and (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9 ^{p. 5}
  • Net of (iv) the cost of reinsurance, (v) taxes, and (vi) minority interests ^{p. 5}
• New business value margin ('NBV Margin'): the ratio of (i) NBV representing the value of newly issued contracts during the current year to (ii) PVEP ^{p. 5}
• Present value of expected premiums ('PVEP'): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term ^{p. 5}
  • PVEP is discounted at the reference interest rate and PVEP is Group share ^{p. 5}
• AA: S&P Global Ratings
• AM: AM Best
• AMF: Autorité des Marchés Financiers
• APM: Alternative Performance Measure
• CLP: Credit and Lifestyle Protection
• CSM: Contractual Service Margin
• DJSI: Dow Jones Sustainability Index
• DPF: Discretionary Participation Features
• EME: Emerging Markets Europe
• ESMA: European Securities and Markets Authority
• GAAP: Generally Accepted Accounting Principles
• GWP: Gross Written Premiums
• IFRS: International Financial Reporting Standards
• II: Solvency II
• LFL: Like-for-Like
• NB CSM: New Business Contractual Service Margin
• NBV: New Business Value
• PVEP: Present Value of Expected Premiums
• PVNBP: Present Value of New Business Premiums
• SFCR: Solvency and Financial Condition Report
• SME: Small and Medium-sized Enterprises
• SRI: Socially Responsible Investing
• UEPS: Underlying Earnings Per Share
• UK: United Kingdom
• UN: United Nations
• UNEP FI: United Nations Environment Programme's Finance Initiative

Scope

• France: includes insurance activities, banking activities, and holding ^{p. 6}
• Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holding), Italy (insurance activities), Prima 13 (insurance activities), AXA Health International (insurance activities), and AXA Life Europe (insurance activities) ^{p. 6}
• AXA XL: includes insurance and reinsurance activities and holding ^{p. 6}
• Asia, Africa & EME-LATAM: ^{p. 6}
  • Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excl. the bancassurance entity), China P&C, South Korea, and Asia Holdings (fully consolidated) ^{p. 6}
  • Asia: China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (the bancassurance entity) (consolidated under the equity method, contributing only to NBV, PVEP, underlying earnings, and net income) ^{p. 6}
  • Africa: Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding) (fully consolidated) ^{p. 6}
  • EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) (fully consolidated) ^{p. 6}
  • EME-LATAM: Russia (Reso) (insurance activities) (consolidated under the equity method, contributing only to net income) ^{p. 6}
  • Also includes AXA Mediterranean Holdings ^{p. 6}
• Transversal & Other: includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (incl. the Group's internal reinsurance activity), and other Central Holdings ^{p. 6}
• AXA Investment Managers: disposal to BNP Paribas completed on July 1, 2025 ^{p. 6}

Exchange rates

End of period and average exchange rates for major currencies against the euro. ^{p. 6}

For 1 Euro	End of Period Exchange rate		Average Exchange rate
USD	1.17	1.15	1.05	1.17
CHF	0.93	0.93	0.95	0.92
GBP	0.87	0.87	0.84	0.87
JPY	184	183	160	184
HKD	9.14	9.03	8.19	9.14

Notes

• Changes in gross written premiums & other revenues, new business value (NBV), present value of expected premiums (PVEP), and new business value margin (NBV Margin) are on a comparable basis (constant forex, scope, and methodology), unless otherwise indicated ^{p. 7}.
• These terms and others are defined in the glossary section of the press release ^{p. 7}.
• The Solvency II ratio estimate includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026 ^{p. 7}.
• This theoretical amount is based on a full-year dividend of EUR 2.32 per share to be paid in 2026 for FY25 and an annual share buyback of EUR 1.25bn announced on February 26, 2026 ^{p. 7}.
• Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects from employee share offerings and stock-based compensation ^{p. 7}.
• Dividends and share buybacks are proposed by the Board, at its discretion, and submitted to AXA's shareholders for approval ^{p. 7}.
• This estimate should not be considered an indication of actual dividend and share buyback amounts for the 2026 financial year ^{p. 7}.
• For information on AXA's internal model and Solvency II disclosures, refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on www.axa.com ^{p. 7}.
• Nat Cat load is defined as normalized natural catastrophe losses expected in a year, expressed as a percentage of gross earned premiums in the same year ^{p. 7}.
• The assumption for Nat Cat load is approximately 4.5 points, assuming no significant deterioration in current operating, pricing, and market conditions ^{p. 7}.
• Expected underlying earnings per share (UEPS) growth for 2026 is a forward-looking statement providing one-off guidance for the last year of the Group's current strategic plan ^{p. 7}.
• General account is referenced ^{p. 7}.
• Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, after which they ceased to qualify as capital under Solvency II ^{p. 7}.
• This was disclosed in AXA's press releases on its 9M25 Activity Indicators and Full Year 2025 Earnings, published on www.axa.com ^{p. 7}.
• Combined ratio is a non-GAAP financial measure (APM) ^{p. 7}.
• Restricted Tier 1 is rated 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's ^{p. 7}.
• Tier 2 is rated 'A' by Standard & Poor's and 'A1 (hyb)' by Moody's ^{p. 7}.
• AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 ^{p. 7}.
• All comments and changes for activity indicators are on a comparable basis (constant forex, scope, and methodology) ^{p. 7}.
• Actuarial and financial assumptions for NBV and PVEP calculations are updated semi-annually at half-year and full-year ^{p. 7}.
• Financial figures and information in this press release have not been audited or subject to limited review by AXA's statutory auditors ^{p. 7}.
• The AXA Group is a worldwide leader in insurance ^{p. 8}.
• AXA has 156,000 employees serving more than 92 million clients in 52 countries ^{p. 8}.
• In 2025, revenues amounted to EUR 115.5bn and underlying earnings to EUR 8.4bn ^{p. 8}.
• The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 - Bloomberg: CS FP - Reuters: AXAF.PA) ^{p. 8}.
• AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY ^{p. 8}.
• The AXA Group is included in main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD ^{p. 8}.
• AXA is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment ^{p. 8}.
• This press release and regulated information are available on the AXA Group website (axa.com) ^{p. 8}.
• Certain statements in the press release are forward-looking, including those regarding expected underlying earnings per share (UEPS) growth for 2026 ^{p. 8}.
• These forward-looking statements provide one-off guidance for the last year of the Group's current strategic plan ^{p. 8}.
• Forward-looking statements are subject to known and unknown risks and uncertainties, many outside AXA's control, which could cause actual results to differ materially ^{p. 8}.
• AXA specifically disclaims any obligation to publicly update or revise forward-looking statements, except as required by applicable laws and regulations ^{p. 8}.
• The press release refers to non-GAAP financial measures (APMs) used by Management for analyzing operating trends, financial performance, and position ^{p. 8}.
• These non-GAAP financial measures generally have no standardized meaning and may not be comparable to similarly labeled measures used by other companies ^{p. 8}.
• Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Group's consolidated financial statements prepared in accordance with IFRS ^{p. 8}.
• Underlying earnings, UEPS, underlying return on equity, combined ratio, and debt gearing are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015 ^{p. 8}.
• Reconciliations of APMs to financial statements are provided in the 2025 Universal Registration Document, Section 2.3.3 'Alternative Performance Measures' ^{p. 8}.
• For more information, Investor Relations can be reached at +33.1.40.75.48.42 or investor.relations@axa.com ^{p. 8}.
• Individual Shareholder Relations can be reached at +33.1.40.75.48.43 ^{p. 8}.
• Media Relations can be reached at +33.1.40.75.46.74 or ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com ^{p. 8}.
• Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments ^{p. 8}.
• SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes ^{p. 8}.

Appendix 1: Earnings

• APPENDIX 1 details gross written premiums & other revenues by geography and business line ^{p. 9}.

Gross written premiums and other revenues by region and business line. ^{p. 9}

EUR million	GWP & Other Revenues					o/w P&C		o/w Life & Health
—	1Q25 Published	1Q25 Adjusted ii,iii	1Q26	Change vs. 1Q25 Adjusted	Change LFL	1Q26	Change LFL	1Q26	Change LFL
France i,ii,iii	8,440	7,923	8,393	+6%	+5%	3,355	+6%	5,012	+4%
Europe iii	15,289	15,608	16,905	+8%	+6%	9,328	+4%	7,577	+9%
AXA XL	6,984	6,984	6,488	-7%	0%	6,459	0%	29	-1%
Asia, Africa & EME-LATAM	5,286	5,286	5,403	+2%	+11%	1,719	+8%	3,684	+13%
Transversal ii	525	723	764	+6%	+6%	601	+8%	163	-2%
AXA Investment Managers	443	443	-	n.m.	n.m.	—	—	—	—
Total i	36,967	36,967	37,953	+3%	+6%	21,462	+4%	16,464	+8%

• Banking revenues were EUR 26m in 1Q26 and EUR 25m in 1Q25 ^{p. 9}.
• Portfolio of lifestyle and income protection (CLP) premiums were reallocated from France to Transversal ^{p. 9}.
  • 1Q25 CLP premiums: EUR 198m (EUR 68m in P&C, EUR 130m in Life & Health) ^{p. 9}.
  • 1Q26 CLP premiums: EUR 201m (EUR 68m in P&C, EUR 132m in Life & Health) ^{p. 9}.
• International protection and health premiums previously recorded in AXA France are now reported under AXA Health International, part of Europe ^{p. 9}.
  • 1Q25 International protection and health premiums: EUR 319m (EUR 104m in Life, EUR 215m in Health) ^{p. 9}.
  • 1Q26 International protection and health premiums: EUR 336m (EUR 103m in Life, EUR 233m in Health) ^{p. 9}.

P&C gross written premiums by commercial, personal, and AXA XL reinsurance lines. ^{p. 10}

EUR million	Commercial lines		Personal lines					AXA XL Reinsurance		Total P&C
—	Total Commercial	Changeⁱ	Personal Motor	Changeⁱ	Personal Non-Motor	Changeⁱ	Total Personal	Changeⁱ	Total Reinsurance	Changeⁱ	1Q26	Changeⁱ
France	2,061	+6%	766	+10%	528	+4%	1,294	+8%	—	—	3,355	+6%
Europe	4,388	+1%	3,370	+10%	1,570	+2%	4,940	+7%	—	—	9,328	+4%
AXA XL	5,215	+2%	—	—	—	—	—	—	1,244	-7%	6,459	0%
Asia, Africa & EME-LATAM	952	+10%	577	+8%	190	+2%	767	+7%	—	—	1,719	+8%
Transversal	601	+8%	—	—	—	—	—	—	—	—	601	+8%
Total	13,217	+3%	4,712	+9%	2,288	+2%	7,001	+7%	1,244	-7%	21,462	+4%

• Changes are presented on a comparable basis (constant forex, scope, and methodology) ^{p. 10}.
• Interest Rates (5Y) are used for the discounting of P&C Claims Reserves ^{p. 10}.

Exchange rates for major currencies in FY25 and 1Q26. ^{p. 10}

—	FY25 i	1Q26 ii
EUR	2.6%	2.7%
USD	4.2%	4.0%
JPY	1.0%	1.6%
GBP	4.3%	4.2%
CHF	0.2%	0.2%
HKD	3.2%	2.8%

P&C price effect by country and business line in 1Q26. ^{p. 11}

1Q26 (in %)	Commercial lines	Personal lines	AXA XL Reinsurance
France	+3.5%	+2.6%	—
Europe	+3.0%	+4.2%	—
Switzerland	+4.0%	+5.1%	—
Germany	+2.5%	+4.2%	—
Belgium & Luxembourg	+2.2%	+2.4%	—
UK & Ireland	+0.5%	-0.9%	—
Spain	+5.7%	+6.0%	—
Italy	+2.7%	+3.8%	—
AXA XL ii	-0.2%	—	-3.9%
Asia, Africa & EME-LATAM	+0.4%	+5.6%	—
Total	+1.5%	+4.0%	-3.9%

• No facts available for this section.

Life & Health gross written premiums by protection, G/A savings, unit-linked, and health. ^{p. 12}

EUR million	Total i		o/w Protection		o/w G/A Savings (footnote: General account.)		o/w Unit-Linked		o/w Health
—	1Q26	Change ii	1Q26	Change ii	1Q26	Change ii	1Q26	Change ii	1Q26	Change ii
France	5,012	+4%	996	+3%	1,325	+1%	1,437	+7%	1,253	+4%
Europe	7,577	+9%	1,986	0%	1,263	+16%	1,044	+24%	3,283	+8%
AXA XL	29	-1%	15	+1%	14	-2%	—	—	—	—
Asia, Africa & EME-LATAM	3,684	+13%	1,764	+10%	319	+27%	224	+35%	1,377	+10%
Transversal	163	-2%	132	-1%	—	—	—	—	31	-5%
Total	16,464	+8%	4,893	+4%	2,922	+9%	2,705	+16%	5,944	+8%
o/w short-term iii	5,436	+6%	1,183	+1%	—	—	—	—	4,253	+7%

• PVEP, NB CSM, NBV, and NBV margin for 1Q25, 1H25, and 9M25 have been updated based on FY25 actuarial and financial assumptions ^{p. 13}.

1Q25 updated figures for life and health business by region. ^{p. 13}

EUR million	Life				Healthⁱ				Totalⁱ
—	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)
Franceⁱⁱ,ⁱⁱⁱ	3,026	94	103	3.4%	1,565	—	44	2.8%	4,591	94	147	3.2%
Europeⁱⁱⁱ	2,982	183	161	5.4%	1,627	74	66	4.0%	4,609	257	227	4.9%
Asia, Africa & EME-LATAM	3,128	178	185	5.9%	612	67	61	9.9%	3,740	245	246	6.6%
Transversalⁱⁱ	63	5	3	5.2%	—	—	—	—	63	5	3	5.2%
Total	9,199	460	452	4.9%	3,805	141	170	4.5%	13,003	601	623	4.8%

1H25 updated figures for life and health business by region. ^{p. 13}

EUR million	Life				Healthᶦ				Totalᶦ
—	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)
France ii,iii	6,969	204	245	3.5%	3,261	—	82	2.5%	10,229	204	327	3.2%
Europe iii	5,585	328	271	4.8%	2,109	83	76	3.6%	7,694	410	347	4.5%
Asia, Africa & EME-LATAM	6,228	389	380	6.1%	1,120	140	120	10.7%	7,347	529	500	6.8%
Transversal ii	153	12	8	5.2%	—	—	—	—	153	12	8	5.2%
Total	18,934	934	904	4.8%	6,490	223	278	4.3%	25,424	1,156	1,182	4.6%

9M25 updated figures for life and health business by region. ^{p. 13}

EUR million	Life				Healthᶦ				Totalᶦ
—	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)	PVNBP	NB CSM (pre-tax)	NBV (post-tax)	NBV margin (%)
France ii,iii	9,911	277	344	3.5%	4,788	—	116	2.4%	14,698	277	459	3.1%
Europe iii	7,900	450	365	4.6%	3,215	114	104	3.2%	11,115	564	469	4.2%
Asia, Africa & EME-LATAM	9,408	600	592	6.3%	1,502	199	167	11.1%	10,910	799	759	7.0%
Transversal ii	230	18	12	5.2%	—	—	—	—	230	18	12	5.2%
Total	27,448	1,345	1,312	4.8%	9,505	313	387	4.1%	36,953	1,659	1,698	4.6%

1Q25 updated figures for NB CSM to NBV for life and health. ^{p. 13}

EUR million	Life	Health i	Total i
NB CSM (pre-tax)	460	141	601
Other NBV (pre-tax)	133	82	215
Tax	-141	-53	-194
Total NBV	452	170	623

1H25 updated figures for NB CSM to NBV for life and health. ^{p. 13}

EUR million	Life	Health i	Total i
NB CSM (pre-tax)	934	223	1,156
Other NBV (pre-tax)	258	144	402
Tax	-288	-89	-377
Total NBV	904	278	1,182

9M25 updated figures for NB CSM to NBV for life and health. ^{p. 13}

EUR million	Life	Healthⁱ	Totalⁱ
NB CSM (pre-tax)	1,345	313	1,659
Other NBV (pre-tax)	384	198	583
Tax	-418	-125	-543
Total NBV	1,312	387	1,698

• APPENDIX 9: OTHER APPENDIX 6 covers PVEP, NB CSM, NBV, and NBV margin ^{p. 14}.
• Changes are compared against 1Q25 updated figures based on FY25 financial and actuarial assumptions ^{p. 14}.

Life and health new business metrics for 1Q26 by region. ^{p. 14}

—	Life New Business Metrics 1Q26								Health i New Business Metrics 1Q26								Total i New Business Metrics 1Q26
France iii,iv	3,348	+11%	96	+2%	112	+8%	3.3%	-0.1 pt	1,815	+16%	—	—	46	+5%	2.5%	-0.3 pt	5,162	+12%	96	+2%	158	+7%	3.1%	-0.1 pt
Europe iv	3,287	+8%	187	-1%	156	-5%	4.8%	-0.7 pt	1,707	+4%	89	+17%	77	+15%	4.5%	+0.4 pt	4,994	+7%	275	+4%	233	0%	4.7%	-0.3 pt
Asia, Africa & EME-LATAM	3,129	+11%	178	+13%	178	+7%	5.7%	-0.2 pt	407	-26%	46	-22%	37	-32%	9.1%	-0.8 pt	3,536	+5%	224	+4%	215	-2%	6.1%	-0.5 pt
Transversal iii	67	+7%	5	+7%	3	+7%	5.2%	0.0 pt	—	—	—	—	—	—	—	—	67	+7%	5	+7%	3	+7%	5.2%	0.0 pt
Total	9,831	+10%	466	+5%	450	+3%	4.6%	-0.3 pt	3,929	+4%	135	-1%	160	-4%	4.1%	-0.4 pt	13,760	+8%	601	+4%	609	+1%	4.4%	-0.3 pt

NB CSM to NBV for life and health. ^{p. 14}

EUR million	Life	Health i	Total i
NB CSM (pre-tax)	466	135	601
Other NBV (pre-tax)	125	73	198
Tax	-142	-48	-190
NBV	450	160	609

• Health business written predominantly in Life entities is included ^{p. 14}.
• Changes are presented on a comparable basis (constant forex, scope, and methodology) ^{p. 14}.
• APPENDIX 9: OTHER APPENDIX 7 covers Life & Health net flows ^{p. 15}.

Net flows by business line

Net flows by business line for 1Q25 and 1Q26. ^{p. 15}

EUR billion	1Q25	1Q26
Health i	+0.8	+1.0
Protection	+1.8	+1.8
G/A Savings	-0.7	-0.8
o/w capital light ii	+0.6	+0.7
o/w traditional G/A	-1.3	-1.5
Unit-Linked iii	+0.5	+0.7
Total Life & Health i net flows	+2.5	+2.7

• Health business written predominantly in Life entities is included ^{p. 15}.
• Capital light G/A encompasses all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% ^{p. 15}.
• Investment contracts with no discretionary participation features ('DPF') are included ^{p. 15}.
• Main transactions in 2026: AXA announced the execution of a share repurchase agreement for its share buyback program of up to EUR 1.25bn on February 27, 2026 ^{p. 16}.
• Next main investor events:
  • HY26 Earnings Release on July 31, 2026 ^{p. 16}.
  • AXA Investor Day on September 15, 2026 ^{p. 16}.
  • AXA Investor roundtable on the strategy for AXA key markets on September 21, 2026 ^{p. 16}.
  • 9M26 Activity Indicators on October 29, 2026 ^{p. 16}.
• APPENDIX 9: OTHER APPENDIX 8 covers main transactions and next main investor events ^{p. 16}.